Masimo (NASDAQ:MASI) Releases Q3 2024 Earnings Guidance

Masimo (NASDAQ:MASI) updated its third quarter 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 0.810-0.860 for the period, compared to the consensus estimate of 0.830. The company issued revenue guidance of $495.0 million-$515.0 million, compared to the consensus revenue estimate of $502.2 million. Masimo also updated its Q3 guidance to $0.81-0.86 EPS.

Analyst Ratings Changes

MASI has been the topic of a number of analyst reports. Piper Sandler lifted their price objective on Masimo from $160.00 to $165.00 and gave the stock an overweight rating in a research report on Wednesday, August 7th. Needham & Company LLC reiterated a hold rating on shares of Masimo in a report on Friday, September 20th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Masimo currently has a consensus rating of Moderate Buy and an average price target of $144.67.

Masimo Price Performance

NASDAQ:MASI opened at $133.20 on Friday. Masimo has a 52 week low of $75.22 and a 52 week high of $153.93. The stock’s fifty day moving average is $116.67 and its two-hundred day moving average is $124.97. The company has a market capitalization of $7.08 billion, a P/E ratio of 90.61 and a beta of 0.98. The company has a quick ratio of 1.15, a current ratio of 2.09 and a debt-to-equity ratio of 0.55.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.09. The company had revenue of $496.30 million during the quarter, compared to analyst estimates of $493.92 million. Masimo had a net margin of 3.94% and a return on equity of 14.07%. Masimo’s revenue was up 9.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.62 earnings per share. Equities analysts expect that Masimo will post 3.87 EPS for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.